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Introduction
Ovarian cancer is the second among gyneco-
logic malignancies in order of frequency and in
Italy it is estimated about 5,000 new cases a year.
Ovarian cancer is the leading cause of death
among gynecologic cancer (3000 patients each year
die from the disease) and represents 5% of all can-
cers(1).
The occurrence of cancer is related to expo-
sure to risks of various kinds, among whom there
are prolonged hormonal action (Fathalla theory),
use of drugs that stimulate ovulation, obesity and,
especially, advanced age(2). In fact, ovarian cancer is
defined as a cancer whose incidence rises with
increasing age: the peak was found at 63 years, but
cases of ovarian cancer increased from 40 years
onwards(2). fig
However, there are cases in which the tumor is
diagnosed in young women and this is due to a
genetic predisposition with alterations of certain
genes, such as the BRCA 1 and 2. Currently the
standard treatment approach involves surgical exci-
sion of the tumor (when feasible) possibly associat-
ed with therapy with Carboplatin as a single agent
or in combination with Paclitaxel.
Other drugs have been tested and are currently
administered in case of resistance or contraindica-
tions (such as adverse reactions) to therapy with
carboplatin and paclitaxel, such as Docetaxel,
Doxorubicin Liposomal Pegylated, Gemcitabine,
Epirubicin and Trabectedin(3-4-5-6-7-8).
In recent years have been also introduced tar-
geted agents (Bevacizumab, Olaparib, Pazopanib,
Cediranib) in the treatment of ovarian cancer with
promising results(9).
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ABSTRACT
The purpose of this statistical analysis is to demonstrate the real advantages in terms of cost-benefit of combination chemothe-
rapy compared with single-agent chemotherapy. The trials, which are used in this meta-analysis, have been searched on PubMed
database and they are phase II or randomized phase III studies with only chemotherapy regimens. In this meta-analysis were evalua-
ted adverse effects with odds ratio (OR), which is expressed in 95% confidence intervals (95% CI). Only 4 studies contained all the
set selection criteria and they were selected. The data, which were obtained, were analyzed using MedCalc Application. The combi-
nation therapy was more strongly linked to certain adverse events than to chemotherapy with a single agent: thrombocytopenia, ane-
mia, neutropenia and nausea. The data obtained for leukopenia, for vomiting and for stomatitis are not statistically significant, as
well as those of antitumor activity. Obtained data allow us to state that the overall combination therapy is more closely related to
adverse effects such as thrombocytopenia, anemia, neutropenia and nausea compared tosingle-agent chemotherapy.
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The stage classification more frequently used
is International Federation of Gynecology and
Obstetrics (FIGO) staging, based on clinical criteria
and especially on surgical staging.
Material and methods 
In this meta-analysis, we wanted to analized
the impact of toxicity of combination therapy
towards the monotherapy in ovarian cancer.
Search strategy
The search for the selection of trials and stud-
ies related to the meta-analysis we consulted
PubMed database with the last updated on April
2015.
The research contained the terms “ovarian
cancer” AND “chemotherapy” and the results were
individually scanned against the selection criteria
set after the search, which allowed to exclude or
select various studies according to their characteris-
tics and their inherence the selection criteria.
Selection criteria
• Randomized trials (Phase IIR studies and
phase III);
• Trials that included only chemotherapy regi-
mens;
• Trials comparing monotherapy and combina-
tion chemotherapy;
• Trials that included toxicity data in various
systems and devices.
From the initial search of PubMed database
emerged 13854 results that by applying gradually
the various selection criteria, have been reduced first
to 195 and then eventually only four have met all
the criteria (Fig 1).
The selected studies included a total of 1553
patients, of course all female, who had attained the
age of eighteen.
The items individually showed a variable
number of patients: the study with fewer patients
had 165, the most numerous 672 patients.
The selected trials are three phase III studies
and one phase II randomized study; in addition,
among the four trials selected, two studies are at
two-arm trials and the other two are three-arm tri-
als, ie, the first compare two populations of patients
and seconds three populations of patients. 
The obtained results from the selection of the
studied articles were carefully analyzed and extract-
ed data were compared in the trials selected.
By comparing the various studies were consid-
ered particular adverse events, such as thrombocy-
topenia, anemia, leukopenia, neutropenia, nausea,
vomiting and stomatitis, while data on the adverse
event diarrhea were not sufficient to carry out the
analytical comparison between studies.
In all studies, the data concerning the side
effects considered the toxicity of grade 3 and grade
4; only data on vomiting in one of four studies also
include patients with the side effect of grade 2 (Tab
1-2-3-4-5-6-7).
Moreover, in some of the selected studies, was
evaluated and analyzed the antitumor activity in
patients examined, in terms of “partial response”
(PR) and “complete response” (CR) (Tab 8).fig
The data extrapolated for adverse events and
antitumor activity were included in the Excel
tables, where they were confronted the effects of
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Figure 1: Studies selection.
TROMBOCITOPENIA Mono N     Mono X Combo N Combo X
PLD vs PLD+trabectedina (OVA-301) 330 4 333 23
Topotecano vs Topotecano+Etoposide 178 24 177 38
Topotecano vs Topotecano+Gemcitabina 178 24 147 46
PLD vs PLD+trabectedina (Barkley Monk J et al.) 330 8 333 61
Paclitaxel vs Paclitaxel+Carboplatino 56 1 51 2
Paclitaxel vs Paclitaxel+Topotecano 56 1 57 4
Table 1: Thrombocytopenia. N: total number of patients;
X: the number of patients who experienced the side effect;
Mono: single-agent therapy; Combo: combination therapy.
combination therapy and those of monotherapy for
every single side effect. The tables are listed in the
Appendix (Tab 1-8).
Statistical analysis 
The data included in the tables for each side
effect and for the antitumor activity were included
in the free trial version of the program “MedCalc
application”, Copyright © 1999-2016
MedCalc.com
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ANEMIA Mono N  Mono X Combo N  Combo X
PLD vs PLD+trabectedina
(OVA-301)
Topotecano vs
Topotecano+Etoposide 178 33 177 53
Topotecano vs
Topotecano+Gemcitabina 178 33 147 26
PLD vs PLD+trabectedina 330 16 333 41
Paclitaxel vs
Paclitaxel+Carboplatino 56 3 51 10
Paclitaxel vs
Paclitaxel+Topotecano 56 3 57 17
NEUTROPENIA Mono N    Mono X Combo N Combo X
PLD vs PLD+trabectedina
(OVA-301) 330 30 333 72
Topotecano vs
Topotecano+Etoposide
Topotecano vs
Topotecano+Gemcitabina
PLD vs PLD+trabectedina
(Barkley Monk J et al.) 330 74 333 209
Paclitaxel vs
Paclitaxel+Carboplatino 56 7 51 28
Paclitaxel vs
Paclitaxel+Topotecano 56 7 57 24
Table 3: Neutropenia. N: total number of patients; X: the
number of patients who experienced the side effect;
Mono: single-agent therapy; Combo: combination the-
rapy.
Table 2: Anemia. N: total number of patients; X: the
number of patients who experienced the side effect;
Mono: single-agent therapy; Combo: combination the-
rapy.
LEUCOPENIA   Mono N Mono X Combo N  Combo X
PLD vs PLD+trabectedi-
na (OVA-301)
Topotecano vs
Topotecano+Etoposide 178 92 177 108
Topotecano vs
Topotecano+Gemcitabina 178 92 147 47
PLD vs PLD+trabectedi-
na(Barkley Monk J et al.) 330 32 333 110
Paclitaxel vs
Paclitaxel+Carboplatino 56 4 51 16
Paclitaxel vs
Paclitaxel+Topotecano 56 4 57 15
Table 4: Leukopenia. N: total number of patients; X: the
number of patients who experienced the side effect;
Mono: single-agent therapy; Combo: combination the-
rapy.
NAUSEA Mono N  Mono X Combo N  Combo X
PLD vs PLD+trabectedina
(OVA-301) 330 2 333 9
Topotecano vs
Topotecano+Etoposide 178 5 177 12
Topotecano vs
Topotecano+Gemcitabina 178 5 147 8
PLD vs
PLD+trabectedina(Barkley
Monk J et al.)
330 8 333 29
Paclitaxel vs
Paclitaxel+Carboplatino
Paclitaxel vs
Paclitaxel+Topotecano
Table 5: Nausea. N: total number of patients; X: the
number of patients who experienced the side effect;
Mono: single-agent therapy; Combo: combination the-
rapy.
VOMITING Mono N   Mono X  Combo N  Combo X
PLD vs PLD+trabectedina
(OVA-301) 330 2 333 111
Topotecano vs
Topotecano+Etoposide 178 7 177 11
Topotecano vs
Topotecano+Gemcitabina 178 7 147 4
PLD vs PLD+trabectedi-
na(Barkley Monk J et al.) 330 7 333 34
Paclitaxel vs
Paclitaxel+Carboplatino 56 10 51 13
Paclitaxel vs
Paclitaxel+Topotecano 56 10 57 14
Table 6: Vomiting. N: total number of patients; X: the
number of patients who experienced the side effect;
Mono: single-agent therapy; Combo: combination the-
rapy.
STOMATITI Mono N  Mono X Combo N  Combo X
PLD vs PLD+trabectedina
(OVA-301) 330 6 333 1
Topotecano vs
Topotecano+Etoposide 178 0 177 2
Topotecano vs
Topotecano+Gemcitabina 178 0 147 0
PLD vs PLD+trabectedi-
na(Barkley Monk J et al.) 330 17 333 3
Paclitaxel vs
Paclitaxel+Carboplatino
Paclitaxel vs
Paclitaxel+Topotecano
Table 7: Stomatitis. N: total number of patients; X: the
number of patients who experienced the side effect;
Mono: single-agent therapy; Combo: combination the-
rapy.
The parameters of the tables have been includ-
ed in the application, in such a way to be considered
as a “control group” patients who had carried out as
monotherapy and “intervention group” patients who
were subjected to combination therapy. 
After entering the data, for each side effect
and for the antitumor activity, the meta-analysis
was performed, with the calculation of odds ratios
(OR) and the automatic construction of graphics. In
this meta-analysis, the OR is used to evaluate the
actual link between the combination of drugs used
and the occurrence of the side effect and the answer
to given by the values of OR obtained.
The values of OR <1 indicates that the factor
under consideration, namely the combination thera-
py, appears to be protective against the side effect
and that monotherapy exposed to a higher risk of
onset of the side effect.
The values of OR> 1, by contrast, demonstrate
that the combination therapy is closely related to
the pathogenesis and the onset of the side effect,
while for values of OR=1 the adverse effect appears
independently from exposure to chemotherapy sin-
gle- agent or combination(9-10-11).
The confidence interval (CI) provides a range
of possible values within which it is estimated to
fall, with a probability level chosen at will, the true
value of the parameter considered in the population.
Actually we are not sure that the sample is
included in this range, but there is a 95% probabili-
ty that it is (95% CI)(13-14).
The heterogeneity of the included studies was
tested using the Cochran Q test, with a significance
level set to 0.1. The meta-analysis of OR was per-
formed to calculate the pooled OR, using the ran-
dom effect or the fixed effect, depending on the sta-
tistical significance of the Q-test, according to the
method of Mantel-Haenszel test.
Results
Studies selected 
Selected studies show the comparison between
the chemotherapy with a single agent and that of
combination, and in particular:
• The study of Monk B.J. et al.(15) compared
therapy with pegylated liposomal doxorubicin as a
single agent and its combination with trabectedin in
patients with recurrent ovarian cancer, after failure
of first-line therapy with platinum-based
chemotherapy regimens;
• The study CARTHAXY carried out by the
GINECO group(16) compares treatment with pacli-
taxel as a single agent and its combination with
topotecan and with carboplatin in patients with
relapsed ovarian cancer, after the first or second
line chemotherapy with platinum and taxane-based,
with disease progression within 6 months after the
last treatment cycle;
• The study OVA-301(17) compares the therapy
with pegylated liposomal doxorubicin as a single
agent and its combination with trabectedin in
patients with recurrent cancer after treatment with
platinum-based regimens, in the presence of plat-
inum-sensitive or partially platinum-sensitive can-
cer;
• The study of German society NOGGO(18)
compares the single-agent therapy with topotecan
and its combination with etoposide and with gemc-
itabine in patients with recurrent cancer after being
treated with primary surgical approach and
chemotherapy (platinum-based regimens).
The data on toxicity and on antitumor activity
were analyzed using MedCalc application, that has
allowed us to study all the individual aspects exam-
ined.
They were considered total values random-
effects, for the results that showed a p-value <0.1,
as with significant heterogeneity in terms of statis-
tics; they were considered instead the total values
fixed-effects for those who had a p-value> 0.1,
because not significant from the point of view of
heterogeneity(14).
Thrombocytopenia 
The analysis found a statistically significant
(OR: 3.722; 95% CI: 1.987 to 6.974) regarding the
parameter thrombocytopenia compared in the two
patient populations analyzed. It is shown that, over-
all, thrombocytopenia occurs more frequently in
patients undergoing combination therapy compared
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ANTITUMOR ACTI-
VITY Mono N Mono PR+CR Combo N Combo PR+CR
Paclitaxel vs
Paclitaxel+Carboplatino 57 20 51 19
Paclitaxel vs
Paclitaxel+Topotecano 57 20 57 22
Topotecano vs
Topotecano+Etoposide 133 37 122 44
Topotecano vs
Topotecano+Gemcitabina 133 37 95 30
Table 8: Antitumor activity. N: total number of patients;
X: the number of patients who experienced the side
effect; Mono: single-agent therapy; Combo: combination
therapy.
to patients which is administered therapy with a
single agent. The pooled OR for thrombocytopenia
was calculated using the random effect, because of
significant heterogeneity between studies (P
<0.001) (Fig 2).
Anemia 
Statistical analysis showed a significant result
(OR: 2.298; 95% CI: 1.259 to 4.193) of the parame-
ter anemia in comparing the combination regimens
and those monotherapy. The pooled OR for anemia
was calculated using the random effect, due to the
significant heterogeneity among the studies (P =
0.007) (Fig 3).
Neutropenia
Results show statistical significance (OR:
4.794; 95% CI: 2.922 to 7.864) of the variable neu-
tropenia in comparison between the combination
and the monotherapy regimens.
All graphs for individual comparisons
revealed greater frequency of neutropenia in the
combination therapy compared to monotherapy. 
The pooled OR for neutropenia was calculated
using the random effect, because of significant het-
erogeneity between studies (P <0.001) (Fig 4).
Leukopenia 
The results of the meta-analyzes highlight how
the leukopenia data are not statistically significant,
since the results are very heterogeneous.
The pooled OR for leukopenia was calculated
using the fixed effect (OR: 1.719; 95%
CI: 1.375 to 2.150), due to no significant
heterogeneity between studies (P =
0.121). (Fig 5)
Nausea 
The interpretation of the results (OR:
3.77; 95% CI: 1.822 to 5.197) shows
that nausea is a side effect that increases
in combination with chemotherapy regi-
mens of two drugs. The pooled OR for nausea was
calculated using the random effect, due to the sig-
nificant heterogeneity among the studies (P <0.001)
(Fig 6).
Vomiting 
The data obtained from the meta-analysis
showed a lack of statistical significance: OR: 3.093;
95% CI: 0.910 to 10.513. The pooled OR
for vomiting was calculated using the
random effect, because of significant het-
erogeneity between studies (P = 0.070)
(Fig 7).
Stomatitis
The pooled OR for the stomatitis was cal-
culated using the fixed effect, due to non-
significant heterogeneity among the stud-
ies (P = 0.224).
Looking at the graph you can see that the
overall results are not statistically significant (OR:
0.269; 95% CI: 0.113 to 0.644) (Fig 8).
Antitumor activity 
The pooled OR for the antitumor activity was
calculated using the fixed effect, due to non-signifi-
cant heterogeneity among the studies (P = 0.150).
From data analysis findings are uncertain and
not statistically significant (OR: 1.262; 95% CI:
0.920 to 1.734) (Fig 9).
Discussion
The standard treatment for ovarian cancer
is carboplatin AUC 6 single-agent or car-
boplatin AUC 5 associated with paclitax-
el 175 mg / m2.
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Fig 2: Thrombocytopenia: meta-analysis results.
Fig 3: Anemia: meta-analysis results.
Fig 4: Neutropenia: meta-analysis results.
Recurrence of ovarian cancer are also treated
with platinum-based regimens (especially in plat-
inum-sensitive cancers), but not platinum-based
monotherapy is the preferred treatment in the plat-
inum-resistant patients. 
Many physicians consider even a not plat-
inum-based single-agent therapy in patients with
platinum-sensitive cancer, since it has been demon-
strated a greater benefit of further platinum-based
treatment. 
Studies of Huinink and Gordon assess the
activity of paclitaxel, Liposomal Doxorubicin and
Topotecan as single agents and the association of
paclitaxel to carboplatin in platinum-sensitive and
platinum-resistant patients, after a first treatment
approach based on platinum. The results
obtained show that the combination ther-
apy is more strongly associated with
improvements in terms of efficacy as
measured both PFS (Progression Free
Survival) and OS (Overall Survival)(15).
Carthaxy study compares three groups of
patients treated respectively with weekly
paclitaxel, with Topotecan and paclitaxel
and with carboplatin and Paclitaxel. The
data extrapolated from the study high-
light that there are no significant differ-
ences between the three patient popula-
tions in terms of PFS and Response Rate.
Therefore, schemes with weekly paclitax-
el are preferred since at equal PFS and
RR (Response Rate), are associated with
less toxicity(16).
The study OVA-301 demonstrated
greater efficacy of the combination of
Doxorubicin Liposomal Pegylated with
Trabectedin compared to only
Doxorubicin Liposomal Pegylated. The
increased effectiveness is evaluated in
terms of OS, where there is a survival
that increases of 3 months (19 VS 22
months): these data are more evident in
platinum sensitive patients, where it is
also noted a reduction in the risk of pro-
gression disease and death(17).
The study of the company NOGGO com-
pares Topotecan as a single agent and its
association with etoposide and with
gemcitabine: single-agent regimens are
considered standard treatment in second-
line therapy in platinum-sensitive and
platinum-refractory patients(18).
The studies do not give unanimous indi-
cation, both in terms of effectiveness,
that of greater or less toxicity associated.
The latest evidence shows how in fact
are encouraging data on regimens targeted agents,
such as anti-VEGF Avastin, which results in
improved survival of four months (12.4 VS 8.4)
associated with the carboplatin or with other
regimes of combination chemotherapy.
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Fig 5: Leukopenia: meta-analysis results.
Fig 6: Nausea: meta-analysis results.
Fig 7: Vomiting: meta-analysis results.
Fig 8: Stomatitis: meta-analysis results.
Fig 9: Antitumor activity: meta-analysis results.
Results even more favorable has encountered
Olaparib, a monoclonal antibody that inhibits PARP
and DNA repair errors, in patients with mutations in
the BRCA 1 and 2. 
Olaparib reduces the risk of disease progres-
sion by 82% and determines an increase of PFS
from 4.3 months to 11.2 months. The most signifi-
cant findings were observed in patients treated with
platinum-based regimens, which later have to
answer they are exposed to Olaparib as mainte-
nance therapy(19).
Conclusions
The systematic review of the literature and the
subsequent meta-analysis performed by virtue of
the data extrapolated from the four selected articles,
gave very different results for the various parame-
ters examined.
The results emerging from the analytical eval-
uation of the data associated with variables vomit-
ing, leukopenia and stomatitis demonstrate how the
features and values of the trails are not considered
fit for the comparison.
The two three-arm studies also reported data
inherent the anti-tumoral activity: analysis of this
data does not allow assessing a better anti-tumoral
activity of the combination therapy, compared to
treatment with a single chemotherapeutic agent.
In the assessment of thrombocytopenia, neu-
tropenia, anemia and nausea related data in combi-
nation therapy and in treatment to single pharmaco-
logical agent, the meta-analysis showed that global-
ly these side effects are associated mainly to the
combination of two drugs.
In conclusion, the analyzed data were extrapo-
lated, however, regardless of the values of the
response to therapy in terms of PFS and OS, so this
goes in part to limit the decision on the most effec-
tive treatment regimen in patients with ovarian can-
cer. This meta-analysis is the beginning of a study
of patients with ovarian cancer aimed not only to
the search of therapy with greater anti-tumoral effi-
cacy, but also to research the therapeutic regimen
that affects as little as possible in the quality of life
of these patients.
For this reason, we should project the interest
of new therapies, such as targeted agents.
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